Rapid point-of-care lipoprotein assays by benchtop NMR spectroscopy

BACKGROUND: Circulating lipoprotein measures such as low-density lipoprotein (LDL) cholesterol and apolipoprotein B are causal biomarkers of cardiovascular risk. These can be quantified quickly and accurately by nuclear magnetic resonance (NMR) spectroscopy, but clinical translation has been slow. We investigated easy-to-operate and affordable benchtop NMR technology as a new means to quantify lipoprotein biomarkers in point-of-care settings. METHODS: Serum samples from 336 individuals were analysed with a benchtop NMR spectrometer operating at 80 MHz and a high-field NMR spectrometer operating at 600 MHz. Glucose, apolipoprotein A-I, apolipoprotein B, total triglycerides, total cholesterol, LDL cholesterol and high-density cholesterol were determined by standard biochemistry. Corresponding NMR-based measures were quantified by linear regression. The 80 MHz dataset included experiments with different scan settings to optimize measurement time (1,987 spectra in total). RESULTS: We identified 32 scans (2 min 8 s) as the minimum runtime for lipoprotein quantification. Total triglycerides and glucose were quantified with the highest accuracy (CV [≤]5.2%, R2 [≥]95%), while LDL cholesterol was more challenging (CV = 10.1%, R2 = 72%) and apolipoprotein B in between (CV = 7.4%, R2 = 74%). Epidemiological correlations between biochemistry assays and sex, obesity, glycemia and blood pressure were reproduced by the corresponding benchtop assays (P [≥]0.11 for difference). CONCLUSIONS: We developed a new lipoprotein quantification method and demonstrated its feasibility for standard lipoprotein analytics. The portability and cost-effectiveness of benchtop NMR make it an appealing choice for research and clinical settings where rapid and robust results on site are an advantage.